Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $67,361.76 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 3,348 shares of Travere Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $20.12, for a total value of $67,361.76. Following the completion of the sale, the chief accounting officer now directly owns 63,654 shares of the company’s stock, valued at approximately $1,280,718.48. This trade represents a 5.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Sandra Calvin also recently made the following trade(s):

• On Wednesday, January 22nd, Sandra Calvin sold 925 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.94, for a total transaction of $17,519.50.
• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.30, for a total transaction of $221,247.00.

Travere Therapeutics Price Performance

Shares of Travere Therapeutics stock opened at $21.10 on Wednesday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $21.56. The company has a 50 day simple moving average of $18.69 and a two-hundred day simple moving average of $15.47.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Guggenheim increased their target price on Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright increased their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, January 15th. Leerink Partners reaffirmed an “outperform” rating and set a $20.00 target price on shares of Travere Therapeutics in a report on Tuesday, October 8th. Piper Sandler increased their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. Finally, Cantor Fitzgerald began coverage on shares of Travere Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating for the company. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Institutional Trading of Travere Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Aigen Investment Management LP bought a new position in Travere Therapeutics in the third quarter valued at $170,000. Oppenheimer & Co. Inc. purchased a new position in shares of Travere Therapeutics in the 3rd quarter worth about $673,000. FMR LLC increased its position in shares of Travere Therapeutics by 27.5% during the 3rd quarter. FMR LLC now owns 147,416 shares of the company’s stock valued at $2,062,000 after purchasing an additional 31,772 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of Travere Therapeutics by 30.2% during the 3rd quarter. Two Sigma Advisers LP now owns 720,400 shares of the company’s stock valued at $10,078,000 after buying an additional 167,100 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Travere Therapeutics by 3.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock worth $24,222,000 after buying an additional 64,744 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.